Key Updates
Moderna shares keep sliding, down 3.87% since the last report to $25.60. The main negative catalyst was the failure of a key CMV vaccine in clinical trials, which analysts had viewed as a potential multi-billion-dollar product. The company halted development after results came back “significantly below expectations.”
Current Trend
The stock shows steady declines across all time frames: –4.66% today, –5.67% week-to-date and –3.54% six-month. The current price of $25.60 reflects a downtrend that accelerated after the CMV setback. Short-term volatility remains elevated ahead of the upcoming Q3 results.
Investment Thesis
The thesis rests on Moderna’s ability to diversify beyond COVID-19 vaccines and expand its mRNA platform into other therapeutic areas. The company is positioned as a leader in mRNA technology with the potential to launch breakthrough drugs in oncology, infectious diseases and rare disorders.
Thesis Status
The thesis is under pressure after the CMV vaccine failure, one of the key post-COVID products. The miss highlights the risks of new-drug development and raises questions about how quickly the company can diversify revenue. However, the long-term upside of the mRNA platform remains intact.
Key Drivers
The primary downside factor was the failure of the CMV vaccine in clinical trials, leading to the program’s termination. Upcoming Q3 results, expected to show sizable losses, add further pressure on the stock.
Technical Picture
The stock trades in a descending channel with bearish sentiment gaining strength. The current level of $25.60 sits near recent lows. Trading volume is elevated on the back of negative news, indicating active selling by institutional investors.
Bull Case
- Long-term potential of the mRNA platform for revolutionary therapies, as noted by Motley Fool analysts
- Innovative capabilities and leadership in mRNA technology provide competitive advantages
- Potential rebound from the current decline if positive clinical data emerge
- Portfolio diversification into oncology and other therapeutic areas
- Opportunity to exceed modest expectations in upcoming earnings
Bear Case
- The CMV vaccine failure, once touted as a potential multi-billion-dollar product, undermines confidence in the pipeline
- Expected significant Q3 losses put pressure on financial results
- Persistent declines across all time frames point to fundamental issues
- High clinical-trial risk inherent to the biotech sector
- Reliance on costly R&D programs with no guaranteed outcomes